Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Amortizatization of Intangibles: 2013-2024

Historic Amortizatization of Intangibles for Ultragenyx Pharmaceutical (RARE) over the last 12 years, with Dec 2024 value amounting to $12.6 million.

  • Ultragenyx Pharmaceutical's Amortizatization of Intangibles fell 77.40% to $704,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 54.31%. This contributed to the annual value of $12.6 million for FY2024, which is 1.70% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Amortizatization of Intangibles of $12.6 million as of FY2024, which was down 1.70% from $12.8 million recorded in FY2023.
  • In the past 5 years, Ultragenyx Pharmaceutical's Amortizatization of Intangibles ranged from a high of $12.8 million in FY2023 and a low of -$6.6 million during FY2021.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Amortizatization of Intangibles value was $12.6 million (recorded in 2024), while the average stood at $7.6 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first slumped by 679.01% in 2021, then surged by 575.81% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Amortizatization of Intangibles (Yearly) stood at -$848,000 in 2020, then tumbled by 679.01% to -$6.6 million in 2021, then soared by 59.14% to -$2.7 million in 2022, then skyrocketed by 575.81% to $12.8 million in 2023, then fell by 1.70% to $12.6 million in 2024.